Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Trial Profile

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin
  • Indications Myocardial infarction; Stroke; Thrombosis; Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms VALIDATE-SWEDEHEART
  • Most Recent Events

    • 18 May 2017 Status changed from active, no longer recruiting to completed.
    • 20 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 20 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top